Get all your news in one place.
100's of premium titles.
One app.
Start reading
The Economic Times
The Economic Times
Business

UNBELIEVABLE: Biocon gets usfda nod for breast cancer biosimilar pebrilzo - The Untold Story

New Delhi: Biopharmaceutical company Biocon Ltd on Monday said it has received approval from the US Food and Drug Administration (FDA) for Pebrilzo (pertuzumab-qcay) injection, a biosimilar to Perjeta, used in the treatment of HER2-positive breast cancer.

Pebrilzo is a monoclonal antibody that treats HER2-positive breast cancer by blocking HER2 receptors on cancer cells. With this approval, Biocon now has five oncology biosimilar therapies approved in the United States, the company said in a regulatory filing.

Sign up to read this article
Read news from 100's of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.